Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Telix Pharmaceuticals (Est) Pty. Ltd., widely recognised as Telix Pharmaceuticals, is a dynamic global biopharmaceutical company based in Melbourne, Australia. Founded in 2017, Telix has rapidly expanded its international footprint with significant operations across the United States, Europe, and Japan, establishing a strong presence in pharmaceutical preparation manufacturing.
The company specialises in the development and commercialisation of innovative diagnostic and therapeutic radiopharmaceuticals, specifically targeting critical areas like urology, oncology, and rare diseases. A notable achievement includes the 2021 regulatory approval of Illuccix® (gallium Ga 68 gozetotide injection), which is now the world’s leading PSMA-PET imaging agent for prostate cancer.
Telix's pioneering approach focuses on leveraging targeted radiation to deliver highly specific diagnostic imaging and therapeutic solutions. This commitment positions them at the forefront of precision medicine, addressing unmet needs for patients facing serious illnesses globally.
-19 vs industry average
Telix Pharmaceuticals (Est) Pty. Ltd.’s score of 23 is lower than 36% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Telix Pharmaceuticals (Est) Pty. Ltd. yet.
Telix Pharmaceuticals (Est) Pty. Ltd., an Australian pharmaceutical preparation manufacturing company, does not have specific carbon emissions data available for 2023. However, its climate commitments are influenced by its parent company, Telix Pharmaceuticals Limited.
While direct emissions data for Telix Pharmaceuticals (Est) Pty. Ltd. is not provided, its climate actions and disclosures are cascaded from Telix Pharmaceuticals Limited, as indicated by its CDP data being sourced from the parent organisation. Further details on specific emissions figures or reduction targets are not publicly available for Telix Pharmaceuticals (Est) Pty. Ltd.
No climate goals have been disclosed for Telix Pharmaceuticals (Est) Pty. Ltd. yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more